Home Jincheng Pharma: Investee Company ApolloBio's VGX-3100 Phase III Trial Meets Primary Efficacy Endpoint

Jincheng Pharma: Investee Company ApolloBio's VGX-3100 Phase III Trial Meets Primary Efficacy Endpoint

May 20, 2026 16:58 CST Updated 17:24